Dubois B, Stehlé B, Lehner J P, Derouesné C, Bourin M, Lamour Y, Blin O, Jourdain G, Alperovitch A
Fédération de Neurologie, Hôpital Salpêtrière 47 Bd de l'hôpital, Paris, France.
Therapie. 1996 Jul-Aug;51(4):444-8.
The availability of new drugs for Alzheimer's disease, with different pharmacological profiles, leads to a redefinition the relevant methodology for developing drugs in this indication, including the inclusion/exclusion criteria, the duration of the studies, and therefore, the relevant guidelines. This was the purpose of the Giens Round-table devoted to the new methodology for drug development in Alzheimer disease.
用于治疗阿尔茨海默病的具有不同药理学特性的新药的出现，促使人们重新定义针对该适应症研发药物的相关方法，包括纳入/排除标准、研究持续时间，进而重新定义相关指南。这就是吉恩斯圆桌会议致力于探讨阿尔茨海默病药物研发新方法的目的所在。
